Regeneron beats second-quarter results estimates on Dupixent sales boost

Regeneron Pharmaceuticals (REGN.O) significantly surpassed Q2 revenue and profit estimates, propelled by robust 22% growth in blockbuster eczema treatment Dupixent sales to $4.34 billion and strong performance from cancer drug Libtayo. This strong showing occurred despite a substantial 25% decline in U.S. Eylea sales to $1.15 billion due to increasing competition, with the overall beat, including adjusted EPS of $12.89, pushing shares up nearly 3% premarket as investors focus on Dupixent's expanding indications and Libtayo's growth potential to offset Eylea's challenges.

Analysis

Regeneron Pharmaceuticals (REGN) reported second-quarter results that significantly surpassed Wall Street estimates, driven by the robust performance of its growth assets which more than compensated for a severe decline in its legacy Eylea franchise. The company posted total revenues of $3.68 billion against a $3.28 billion forecast, and an adjusted EPS of $12.89, trouncing the consensus estimate of $8.44. The primary catalyst was the anti-inflammatory drug Dupixent, which saw sales surge 22% to $4.34 billion, exceeding expectations of $4.14 billion and reinforcing its role as the company's core growth driver. This was further supported by the cancer treatment Libtayo, which generated $377 million in sales against a $338.75 million estimate. However, this strength was contrasted by a sharp 25% drop in U.S. sales for the eye disease drug Eylea to $1.15 billion, a figure that starkly missed the $2.17 billion analyst expectation, underscoring the intense competitive pressure from rival drugs like Roche's Vabysmo and cheaper alternatives. The positive premarket stock reaction of nearly 3% indicates investors are currently prioritizing the outperformance of Dupixent and Libtayo over the erosion of Eylea's market share, though a regulatory overhang exists with the company being targeted for U.S. drug price reductions.

Key Decisions for Investors

• Investors should weigh the significant outperformance of Dupixent and Libtayo against the accelerated and deeper-than-expected decline of Eylea, whose 25% sales drop suggests competitive pressures are intensifying rapidly.
• The investment thesis for Regeneron now relies more heavily on Dupixent's continued market expansion, especially in new indications like COPD, to offset the structural erosion in the Eylea franchise.
• Monitor developments related to U.S. drug pricing policy, as the letter received from the administration represents a material regulatory risk that could impact long-term profitability and valuation multiples for the entire sector.